Table 2.
The generation of anti-chaperone antibodies in autoimmune diseases and cancers.
| Disease | Anti-chaperone | Reference |
|---|---|---|
| AUTOIMMUNE DISEASES | ||
| Autoimmune hepatitis | Anti-ERp57 IgG | (67) |
| Inflammatory bowel disease | Anti-calreticulin/BiP IgG | (44, 68) |
| Juvenile idiopathic arthritis | Anti-BiP IgG | (40) |
| Myasthenia gravis | Anti-GRP94 IgG | (69) |
| Primary biliary cirrhosis | Anti-calreticulin IgA | (70) |
| Rheumatoid arthritis | Anti-calreticulin/BiP/GRP94/calnexin IgG | (43, 44, 71) |
| SLE | Anti-calreticulin IgG/anti-PDI IgG/BiP/GRP94/calnexin | (44, 72, 73) |
| Systemic sclerosis | Anti-BiP/GRP94/calnexin IgG | (44) |
| CANCERS | ||
| Colorectal carcinoma | Anti-BiP IgG | (74) |
| Refractory celiac disease | Anti-calreticulin IgA | (75) |
| Pancreatic cancer | Anti-calreticulin IgG | (76) |
| Melanoma | Anti-GRP94 | (77) |
| Hepatoma | Anti-PDI IgG | (73) |